| Title: | A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases |
| Journal: | American Journal of Human Genetics |
| Published: | 24 Aug 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/36007526/ |
| DOI: | https://doi.org/10.1016/j.ajhg.2022.08.003 |
| Citations: | 74 (62 in last 2 years) as of 8 Aug 2024 |
Publication 12263
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Newborn screening (NBS) dramatically improves outcomes in severe childhood disorders by treatment before symptom onset. In many genetic diseases, however, outcomes remain poor because NBS has lagged behind drug development. Rapid whole-genome sequencing (rWGS) is attractive for comprehensive NBS because it concomitantly examines almost all genetic diseases and is gaining acceptance for genetic disease diagnosis in ill newborns. We describe prototypic methods for scalable, parentally consented, feedback-informed NBS and diagnosis of genetic diseases by rWGS and virtual, acute management guidance (NBS-rWGS). Using established criteria and the Delphi method, we reviewed 457 genetic diseases for NBS-rWGS, retaining 388 (85%) with effective treatments. Simulated NBS-rWGS in 454,707 UK Biobank subjects with 29,865 pathogenic or likely pathogenic variants associated with 388 disorders had a true negative rate (specificity) of 99.7% following root cause analysis. In 2,208 critically ill children with suspected genetic disorders and 2,168 of their parents, simulated NBS-rWGS for 388 disorders identified 104 (87%) of 119 diagnoses previously made by rWGS and 15 findings not previously reported (NBS-rWGS negative predictive value 99.6%, true positive rate [sensitivity] 88.8%). Retrospective NBS-rWGS diagnosed 15 children with disorders that had been undetected by conventional NBS. In 43 of the 104 children, had NBS-rWGS-based interventions been started on day of life 5, the Delphi consensus was that symptoms could have been avoided completely in seven critically ill children, mostly in 21, and partially in 13. We invite groups worldwide to refine these NBS-rWGS conditions and join us to prospectively examine clinical utility and cost effectiveness.</p>
8 Keywords
- Child
- Critical Illness
- Genetic Testing
- Humans
- Infant, Newborn
- Neonatal Screening
- Precision Medicine
- Retrospective Studies
51 Authors
- Stephen F. Kingsmore
- Laurie D. Smith
- Chris M. Kunard
- Matthew Bainbridge
- Sergey Batalov
- Wendy Benson
- Eric Blincow
- Sara Caylor
- Christina Chambers
- Guillermo Del Angel
- David P. Dimmock
- Yan Ding
- Katarzyna Ellsworth
- Annette Feigenbaum
- Erwin Frise
- Robert C. Green
- Lucia Guidugli
- Kevin P. Hall
- Christian Hansen
- Charlotte A. Hobbs
- Scott D. Kahn
- Mark Kiel
- Lucita Van Der Kraan
- Chad Krilow
- Yong H. Kwon
- Lakshminarasimha Madhavrao
- Jennie Le
- Sebastien Lefebvre
- Rebecca Mardach
- William R. Mowrey
- Danny Oh
- Mallory J. Owen
- George Powley
- Gunter Scharer
- Seth Shelnutt
- Mari Tokita
- Shyamal S. Mehtalia
- Albert Oriol
- Stavros Papadopoulos
- James Perry
- Edwin Rosales
- Erica Sanford
- Steve Schwartz
- Duke Tran
- Martin G. Reese
- Meredith Wright
- Narayanan Veeraraghavan
- Kristen Wigby
- Mary J. Willis
- Aaron R. Wolen
- Thomas Defay.
1 Application
| Application ID | Title |
|---|---|
| 82213 | Validation of variant pathogenicity and penetrance for genetic screening applications |
Enabling scientific discoveries that improve human health